메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
박지현 (한국화이자제약) 정재홍 (한국화이자제약)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제4권 제2호
발행연도
2016.12
수록면
75 - 81 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objectives: Dexmedetomidine was shown in two randomized clinical trials (MIDEX and PRO- DEX studies) to be non-inferior to midazolam and propofol in maintaining light to moderate seda- tion levels in mechanically ventilated intensive care unit (ICU) patients. In addition, compared with midazolam and propofol, dexmedetomidine shortens the time to extubation and the time spent in ICU. Based on the resource utilization data from these studies, we perform a cost-minimization analy- sis to assess the economic impact of dexmedetomidine versus midazolam and propofol. Methods: This analysis estimates the total healthcare costs in an ICU from a healthcare system perspective. The healthcare costs comprise the costs of medication, administration, test/diagnostic examina- tions, and the treatment of adverse events. Results: Based on MIDEX and PRODEX studies, seda- tion with dexmedetomidine resulted in lower total costs than when using midazolam or propofol. The total cost of dexmedetomidine was estimated at 2874367 KRW in the MIDEX study and 2280374 KRW in the PRODEX study. The cost difference between midazolam and propofol treat- ments were 369179 KRW and 311088 KRW, respectively shown in the two studies. An additional sensitivity analysis confirmed that dexmedetomidine has a lower cost than those of the compara- tors. Conclusion: From an economic point of view, dexmedetomidine is a cheaper treatment option than either midazolam or propofol when providing light to moderate sedation levels in mechanically ventilated ICU patients.

목차

등록된 정보가 없습니다.

참고문헌 (19)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0